FDA Approves New Weight Loss Drug Formulation

The FDA has approved BELVIQ XR (lorcaserin HCI) CIV extended-release 20 mg tablets as a once-a-day option for patients to help achieve and maintain weight loss.

Both the original 10 mg twice-daily formulation and new 20 mg once-daily extended release formulation are intended for use in combination with a reduced-calorie diet and increased physical activity for the management of weight in adults with body mass index of 30 kg/m² or greater, or with a BMI of 27 kg/m² and at least 1 weight-related medical condition.
______________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Which Prescription Weight Loss Drugs Are Most Effective?
Mediterranean Diet Better Than Low-Fat Diet for Weight Loss?
______________________________________________________________________________________________________________________________________________________________________

Possible adverse events include changes in attention or memory, hallucinations, depression, low blood sugar, and slow heartbeat.

—Michael Potts

Reference:

Eisai. Eisai Inc. and Arena Pharmaceuticals Announce FDA approval of BELVIQ XR® (lorcaserin HCl) extended-release tablets [press release]. July 19, 2016. http://www.prnewswire.com/news-releases/eisai-inc-and-arena-pharmaceuticals-announce-fda-approval-of-belviq-xr-lorcaserin-hcl-extended-release-tablets-300300610.html.